Glioblastomas exploit truncated O <i>-</i> linked glycans for local and distant immune modulation via the macrophage galactose-type lectin

Sophie A. Dusoswa, Jan Verhoeff, Erik R. Abels, Santiago P. Méndez‐Huergo, Diego O. Croci, Lisan H Kuijper, Elena de Miguel, Valérie M. Wouters, Myron G. Best, Ernesto Rodríguez,

Proceedings of the National Academy of Sciences · 2020 · 85 citations · 58 references

DOIFull text

Open access

Concepts

Abstract

Glioblastoma is the most aggressive brain malignancy, for which immunotherapy has failed to prolong survival. Glioblastoma-associated immune infiltrates are dominated by tumor-associated macrophages and microglia (TAMs), which are key mediators of immune suppression and resistance to immunotherapy. We and others demonstrated aberrant expression of glycans in different cancer types. These tumor-associated glycans trigger inhibitory signaling in TAMs through glycan-binding receptors. We investigated the glioblastoma glycocalyx as a tumor-intrinsic immune suppressor. We detected increased expression of both tumor-associated truncated O-linked glycans and their receptor, macrophage galactose-type lectin (MGL), on CD163 + TAMs in glioblastoma patient-derived tumor tissues. In an immunocompetent orthotopic glioma mouse model overexpressing truncated O-linked glycans (MGL ligands), high-dimensional mass cytometry revealed a wide heterogeneity of infiltrating myeloid cells with increased infiltration of PD-L1 + TAMs as well as distant alterations in the bone marrow (BM). Our results demonstrate that glioblastomas exploit cell surface O-linked glycans for local and distant immune modulation.

References

58